CN113509465A - 一种具有抗高血压作用的组合物及其应用 - Google Patents
一种具有抗高血压作用的组合物及其应用 Download PDFInfo
- Publication number
- CN113509465A CN113509465A CN202110776429.XA CN202110776429A CN113509465A CN 113509465 A CN113509465 A CN 113509465A CN 202110776429 A CN202110776429 A CN 202110776429A CN 113509465 A CN113509465 A CN 113509465A
- Authority
- CN
- China
- Prior art keywords
- composition
- helenalin
- chinese medicine
- traditional chinese
- antihypertensive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 230000003276 anti-hypertensive effect Effects 0.000 title claims abstract description 10
- ZVLOPMNVFLSSAA-XEPQRQSNSA-N helenalin Chemical compound C[C@@H]1C[C@H]2OC(=O)C(=C)[C@H]2[C@H](O)[C@]2(C)C(=O)C=C[C@@H]12 ZVLOPMNVFLSSAA-XEPQRQSNSA-N 0.000 claims abstract description 21
- OSSDUQKWVVZIGP-UHFFFAOYSA-N Aromaticin Natural products CC1CC2OC(=O)C(=C)C2CC2(C)C(=O)C=CC12 OSSDUQKWVVZIGP-UHFFFAOYSA-N 0.000 claims abstract description 20
- ZVLOPMNVFLSSAA-UHFFFAOYSA-N Heleanalin Natural products CC1CC2OC(=O)C(=C)C2C(O)C2(C)C(=O)C=CC12 ZVLOPMNVFLSSAA-UHFFFAOYSA-N 0.000 claims abstract description 20
- RFBYGVGDYMSKTD-UHFFFAOYSA-N Helenalin Natural products CC1CC2OC(=O)C(=C)C2C(O)C3C(C)C(=O)C=C13 RFBYGVGDYMSKTD-UHFFFAOYSA-N 0.000 claims abstract description 20
- AFTUDGRDUWDYHE-UHFFFAOYSA-N Mexicanin I Natural products CC1CC2OC(=O)C(=C)C2C(O)C3(C)C1CC=C3C AFTUDGRDUWDYHE-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000003814 drug Substances 0.000 claims abstract description 15
- FFVRRQMGGGTQRH-DTPILHQWSA-N tabernaemontanine Chemical compound C1C(C2=CC=CC=C2N2)=C2C(=O)C[C@H]2[C@H](CC)CN(C)[C@@H]1[C@H]2C(=O)OC FFVRRQMGGGTQRH-DTPILHQWSA-N 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 239000002220 antihypertensive agent Substances 0.000 claims description 2
- 229940127088 antihypertensive drug Drugs 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 240000005959 Abelmoschus manihot Species 0.000 claims 1
- 235000001075 Abelmoschus manihot Nutrition 0.000 claims 1
- 244000020551 Helianthus annuus Species 0.000 claims 1
- 235000003222 Helianthus annuus Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 abstract description 16
- 239000000178 monomer Substances 0.000 abstract description 14
- 238000002474 experimental method Methods 0.000 abstract description 10
- 241000700159 Rattus Species 0.000 abstract description 9
- 230000004872 arterial blood pressure Effects 0.000 abstract description 7
- 230000035488 systolic blood pressure Effects 0.000 abstract description 7
- 238000000034 method Methods 0.000 abstract description 4
- 230000002269 spontaneous effect Effects 0.000 abstract description 4
- 206010067482 No adverse event Diseases 0.000 abstract description 2
- 230000008506 pathogenesis Effects 0.000 abstract description 2
- 230000004069 differentiation Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 8
- 230000036772 blood pressure Effects 0.000 description 6
- SJBJYGYLCQECRD-UHFFFAOYSA-N Tabernaemontanine Natural products CCC1CN(C)C2CC3C4CCCCC4NC3C(=O)CC1C2C(=O)OC SJBJYGYLCQECRD-UHFFFAOYSA-N 0.000 description 5
- 229920002261 Corn starch Polymers 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 3
- 241000208688 Eucommia Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 230000003205 diastolic effect Effects 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 241001075517 Abelmoschus Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000008233 Toll-Like Receptor 4 Human genes 0.000 description 1
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000010832 independent-sample T-test Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000011706 wistar kyoto rat Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8988—Gastrodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种具有抗高血压作用的组合物及其应用，它由Tabernemontanine和Helenalin组成。本发明根据高血压的发病机制，在中医药理论的指导下，辨证论治通过大量实验筛选中药单体组方及其用量配比，实验结果表明，本发明提供的中药单体组合物Tabernemontanine和Helenalin可以明显降低自发性高血压（SHR）大鼠收缩压（SBP）和平均动脉压（MBP），并且实验过程中未发现不良反应，临床应用安全。
Description
技术领域
本发明涉及一种组合物，具体涉及一种具有抗高血压作用的组合物及其应用。
背景技术
高血压是指以体循环动脉血压(收缩压和/或舒张压)增高为主要特征(收缩压≥140毫米汞柱，舒张压≥90毫米汞柱)，可伴有心、脑、肾等器官的功能或器质性损害的临床综合征。降压治疗的最终目的是最大限度地减少高血压患者心、脑血管病的发生率和死亡率。临床实验结合荟萃分析结果表明抗高血压的治疗应该在心血管损害前开始，这与中医药“治未病”的理念不谋而合。
天麻、杜仲是常用的高血压中药，本发明采用网络药理学方法筛选出杜仲中的单体成分(-)Tabernemontanine和天麻中的单体成分Helenalin具有治疗高血压的作用。现代药理学表明(-)Tabernemontanine是杜仲治疗腰椎间盘突出症的主要成分之一；Helenalin是具有抗炎作用的倍半萜，抑制Toll样受体4激活。本发明体内实验表明(-)Tabernemontanine和Helenalin联合应用对自发性高血压(SHR)大鼠模型具有明显的治疗作用，可显著降低收缩压(SBP)和平均动脉压(MBP)。
目前，尚没有资料显示(-)Tabernemontanine和Helenalin的中药组合物临床上用于治疗高血压；因此，很有必要在现有技术的基础上研发出一种具有很好防治高血压功效，且不良反应低的中药单体组合物。
发明内容
发明目的：本发明的目的是为了解决现有技术的不足，开发出一种含有Tabernemontanine和Helenalin组合物及其在用于治疗高血压基本中的应用。
技术方案：本发明采用的技术方案为：
一种具有抗高血压作用的组合物，它由Tabernemontanine和Helenalin组成。
作为优选方案，以上所述的具有抗高血压作用的组合物，它由重量比为1～4：1～5的Tabernemontanine和Helenalin组成。Tabernemontanine分子式为：C21H26N2O3，CAS号为：2134-98-7。Helenalin分子式为C15H18O4，CAS号为：6754-13-8。
作为更优选方案，以上所述的黄蜀葵花物在制备防治炎性肠病药物中的应用，它由重量比为4:5的Tabernemontanine和Helenalin组成。
本发明体内实验表明(-)Tabernemontanine和Helenalin联合应用对自发性高血压(SHR)大鼠模型具有明显的治疗作用，可显著降低收缩压(SBP)和平均动脉压(MBP)。可以开发成为抗高血压的药物。
本发明将组合物和药学上可接受的载体制备成颗粒剂、片剂、注射剂、丸剂、胶囊剂或口服液制剂。
本发明在制成片剂时把有效成分细粉添加载体乳糖或玉米淀粉，需要时加入润滑剂硬脂酸镁，混合均匀，然后压片制成片剂。
在制成胶囊剂时，把有效成分细粉添加载体乳糖或玉米淀粉混合均匀，整粒，然后装胶囊制成胶囊剂。
本发明在制成颗粒剂时，把有效成分细粉和稀释剂乳糖或玉米淀粉混合均匀，整粒，干燥，制成颗粒剂。
有益效果：本发明提供的具有防治高血压作用的组合物和现有技术相比具有以下优点：
(1)本发明提供的具有防治高血压作用的组合物，根据高血压的发病机制，在中医药理论的指导下，辨证论治通过大量实验筛选中药单体组方及其用量配比，实验结果表明，本发明提供的中药单体组合物Tabernemontanine和Helenalin可以明显降低自发性高血压(SHR)大鼠收缩压(SBP)和平均动脉压(MBP)，并且实验过程中未发现不良反应，临床应用安全。
(2)本发明提供的具有防治高血压作用的中药单体组合物，可以方便和药学载体制备成多种剂型，临床上服用方便，且实验结果表明本发明提供的中药单体组合物，疗效可靠，使用安全，长期服用无毒副作用。
具体实施方式
根据下述实施例，可以更好地理解本发明。然而，本领域的技术人员容易理解，实施例所描述的具体的物料配比、工艺条件及其结果仅用于说明本发明，而不应当也不会限制权利要求书中所详细描述的本发明。
实施例1药理学实验
1实验材料
1.1实验动物：WKY和SHR大鼠，雄性，由浙江维通利华实验动物技术有限公司提供，动物许可证号：SCXK(浙)2009-0001。
1.2仪器：无创血压仪由北京软隆生物技术有限公司提供。
2、实验方法：
2.1中药单体组合物对自发性高血压大鼠血压的影响
取雄性SHR大鼠12只，9周龄，适应性饲养1周后，随机分为7组，即模型组和不同重量比1:0、0:1、1:1、1:1.25、1:2、2:1的Tabernemontanine和Helenalin中药单体组合物组。WKY大鼠作为对照组。各组大鼠适应性饲养一周后，不同重量比的中药单体组合物组灌胃给予(-)Tabernemontanine(5mg/kg)和Helenalin组合物(5mg/kg)，连续给药7天，对照组和模型组给予相同体积的蒸馏水。采用无创血压仪测定大鼠血压，记录大鼠收缩压(SBP)、平均动脉压(MBP)和舒张压(DBP)。
2.2统计学处理
结果采用
表示，样本统计分析采用独立样本t检验。
3、实验结果：
3.1中药单体组合物对自发性高血压大鼠血压的影响
与对照组大鼠比较，模型组SHR大鼠收缩压(SBP)、平均动脉压(MBP)和舒张压(DBP)显著升高(*p<0.05)；与模型组比较，本发明所提供中药单体组合物显著降低大鼠收缩压(SBP)和平均动脉压(MBP)(*p<0.05)。结果见表1所示：
表1中药单体组合物对自发性高血压(SHR)大鼠血压的影响(
n＝6)
与正常对照组相比，#P<0.05，##P<0.01,###P<0.001；与模型组相比，*P<0.05，
通过以上表1可以看出，本发明通过不同重量比的Tabernemontanine和Helenalin组合物和单个的Tabernemontanine或Helenalin相比较，发现重量比为1:1.25(4:5)的Tabernemontanine和Helenalin组合物将血压作用最优，取得了显著的协同增效的作用。
以上实施方式只为说明本发明的技术构思及特点，其目的在于让熟悉此项技术的人了解本发明内容并加以实施，并不能以此限制本发明的保护范围，凡根据本发明精神实质所做的等效变化或修饰，都应涵盖在本发明的保护范围内。
Claims (5)
1.一种具有抗高血压作用的组合物，其特征在于，它由Tabernemontanine 和/或Helenalin 组成。
2.根据权利要求1所述的具有抗高血压作用的组合物，其特征在于，它由重量比为1~4：1~5的Tabernemontanine 和Helenalin 组成。
3.根据权利要求2所述的黄蜀葵花物在制备防治炎性肠病药物中的应用，其特征在于，它由重量比为4:5的Tabernemontanine 和Helenalin 组成。
4.权利要求1~3任一项所述的具有抗高血压作用的组合物在制备抗高血压的药物中的应用。
5.根据权利要求4所述的应用，其特征在于，将组合物和药学上可接受的载体制备成颗粒剂、片剂、注射剂、丸剂、胶囊剂或口服液制剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110776429.XA CN113509465A (zh) | 2021-07-09 | 2021-07-09 | 一种具有抗高血压作用的组合物及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110776429.XA CN113509465A (zh) | 2021-07-09 | 2021-07-09 | 一种具有抗高血压作用的组合物及其应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113509465A true CN113509465A (zh) | 2021-10-19 |
Family
ID=78066724
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110776429.XA Pending CN113509465A (zh) | 2021-07-09 | 2021-07-09 | 一种具有抗高血压作用的组合物及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113509465A (zh) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107648479A (zh) * | 2017-11-06 | 2018-02-02 | 谭元生 | 一种用于治疗高血压的中药组方及其制品 |
-
2021
- 2021-07-09 CN CN202110776429.XA patent/CN113509465A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107648479A (zh) * | 2017-11-06 | 2018-02-02 | 谭元生 | 一种用于治疗高血压的中药组方及其制品 |
Non-Patent Citations (2)
| Title |
|---|
| YAN LI等: "Investigation into the mechanism of Eucommia ulmoides Oliv. Based on a systems pharmacology approach", 《JOURNAL OF ETHNOPHARMACOLOGY》 * |
| 叶小彤等: "基于"中药作用机理辅助解析系统"的杜仲抗高血压作用机制研究", 《中国中药杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0988028B1 (en) | Use of a composition comprising capsaicin or resiniferatoxin for the treatment of Irritable Bowel Syndrome | |
| WO2016029868A1 (zh) | 用于减少体重及减少体脂肪的组合物及其医药品与应用 | |
| KR101493016B1 (ko) | 중약 조성물의 새로운 용도 | |
| US20060240101A1 (en) | Orally disintegrating pharmaceutical tablet formulations of olanzapine | |
| CN106573029B (zh) | 用于治疗睡眠障碍的缬草根提取物和薰衣草油的组合物 | |
| CN103893571B (zh) | 一种治疗高血压的药物组合物及其应用 | |
| WO2015024218A1 (zh) | 一种药物组合物及其制备方法和用途 | |
| JP2011522844A (ja) | 血糖レベルを低下させる組成物及びその用途 | |
| WO2011088715A1 (zh) | 芍药内酯苷的抗帕金森症用途 | |
| CN109662967B (zh) | 一种抗抑郁药物及其用途 | |
| CN101574339B (zh) | β-脱水淫羊藿素在制备防治心脑血管疾病药物中的应用 | |
| CN113509465A (zh) | 一种具有抗高血压作用的组合物及其应用 | |
| KR101912191B1 (ko) | 모사프리드 또는 이의 염을 포함하는 약제학적 제제 및 이의 제조방법 | |
| CN103655969B (zh) | 一种具有调节血压、血糖功能的中药组合物及其制备方法 | |
| CN110101690B (zh) | 一种神经细胞保护剂及其在癫痫防治中的应用 | |
| CN106038566B (zh) | 一种用于胃癌治疗的药物组合物及其应用 | |
| CN111265618B (zh) | 鼓槌石斛提取物及毛兰素的医药用途 | |
| CN1733207A (zh) | 一种用于治疗原发性低血压病的药物组合物 | |
| CN112316125B (zh) | 一种基于水蛭素的中药组合物及其微丸的制备方法 | |
| CN107951872B (zh) | 一种治疗糖尿病的口服药物组合物 | |
| CN115887396B (zh) | 一种醋甲唑胺口崩片及其制备方法和应用 | |
| KR102268670B1 (ko) | 비만 및 과체중 예방 또는 개선용 약학 조성물, 그리고 그 제조방법 | |
| CN113577090B (zh) | 牛蒡子苷在制备前列腺增生药物中的应用 | |
| CN107998117B (zh) | 一种治疗毛细血管渗漏综合征的口服药物组合物 | |
| JP6938315B2 (ja) | 錠剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211019 |
|
| RJ01 | Rejection of invention patent application after publication |